Phase 2 Study to Evaluate the Safety and Efficacy of IZN-6N4 for the Prevention of Chemo-Radiation-Induced Oral Mucositis in Patients With Head and Neck Cancer
Phase of Trial: Phase II
Latest Information Update: 11 Oct 2017
At a glance
- Drugs IZN 6N4 (Primary)
- Indications Stomatitis
- Focus Therapeutic Use
- Sponsors Izun Pharma
- 11 Oct 2017 Status changed from active, no longer recruiting to completed, according to an Izun Pharma media release.
- 17 Nov 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Jan 2017.
- 13 Nov 2016 Status changed from recruiting to active, no longer recruiting.